A list of other trial(s) currently underway that may benefit patients with Usher syndrome. Please refer to the link under each trial for more information on that trial. Please be aware that all information provided are for informational purposes only, and are in no way endorsed or approved by Usher Syndrome Ireland.
Phase 1/2
- Nacuity Pharmaceuticals focuses on the treatment of ocular oxidative stress in the retina which they believe may potentially slow down the degeneration of the photoreceptors cells as experienced by patients with RP. Their trial, SLO-RP, is currently enrolling patients in Australia with Usher syndrome in stage 1/2 to test the safety and efficacy of NP1-001 tablets over 24 months. More information can be found here: https://www.nacuity.com/pipeline/ and https://clinicaltrials.gov/.
Pre-Clinical Stage
- Sparing Vision hopes to begin phase1/2 by end of 2021 for RP patients, independent of mutation, meaning it could potentially benefit patients with Usher syndrome. Sparing Vision’s therapy focuses on the use of RdCVF (Rod-derived cone viability factor) to express a protein in order to preserve the health and function of cone cells in the retina. More information can be found here: https://www.sparingvision.com/en/pipeline?id=62